7ZYJ image
Deposition Date 2022-05-24
Release Date 2022-09-28
Last Version Date 2024-07-24
Entry Detail
PDB ID:
7ZYJ
Keywords:
Title:
Leishmania tarentolae proteasome 20S subunit in complex with compound 2
Biological Source:
Source Organism:
Method Details:
Experimental Method:
Resolution:
2.70 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Proteasome subunit alpha type
Gene (Uniprot):LtaPh_3548400
Chain IDs:A, O (auth: a)
Chain Length:250
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome subunit alpha type
Gene (Uniprot):LtaPh_2120300
Chain IDs:B, P (auth: b)
Chain Length:231
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome subunit alpha type
Gene (Uniprot):LtaPh_1402900
Chain IDs:C, Q (auth: c)
Chain Length:285
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome subunit alpha type
Gene (Uniprot):LtaPh_1102600, LtaPh_9916201
Chain IDs:D, R (auth: d)
Chain Length:248
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome alpha 5 subunit, putative
Gene (Uniprot):LtaPh_2121400
Chain IDs:E, S (auth: e)
Chain Length:344
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome alpha 1 subunit, putative
Gene (Uniprot):LtaPh_3616000
Chain IDs:F, T (auth: f)
Chain Length:428
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome alpha 7 subunit, putative
Gene (Uniprot):LtaPh_2701900
Chain IDs:G, U (auth: g)
Chain Length:238
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome subunit beta
Gene (Uniprot):LtaPh_1200300
Chain IDs:H, V (auth: h)
Chain Length:229
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome subunit beta
Gene (Uniprot):LtaPh_3538500
Chain IDs:I, W (auth: i)
Chain Length:225
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome subunit beta
Gene (Uniprot):LtaPh_2801100
Chain IDs:J, X (auth: j)
Chain Length:205
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome subunit beta
Gene (Uniprot):LtaPh_3603100
Chain IDs:K, Y (auth: k)
Chain Length:206
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome subunit beta
Gene (Uniprot):LtaPh_3616400
Chain IDs:L, Z (auth: l)
Chain Length:203
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome beta 6 subunit, putative
Gene (Uniprot):LtaPh_0601100
Chain IDs:M, AA (auth: m)
Chain Length:339
Number of Molecules:2
Biological Source:Leishmania tarentolae
Polymer Type:polypeptide(L)
Molecule:Proteasome subunit beta
Gene (Uniprot):LtaPh_2716500, LtaPh_3442751
Chain IDs:N, BA (auth: n)
Chain Length:219
Number of Molecules:2
Biological Source:Leishmania tarentolae
Ligand Molecules
Primary Citation

Abstact

Human African Trypanosomiasis (HAT) is a vector-borne disease caused by kinetoplastid parasites of the Trypanosoma genus. The disease proceeds in two stages, with a hemolymphatic blood stage and a meningo-encephalic brain stage. In the latter stage, the parasite causes irreversible damage to the brain leading to sleep cycle disruption and is fatal if untreated. An orally bioavailable treatment is highly desirable. In this study, we present a brain-penetrant, parasite-selective 20S proteasome inhibitor that was rapidly optimized from an HTS singleton hit to drug candidate compound 7 that showed cure in a stage II mouse efficacy model. Here, we describe hit expansion and lead optimization campaign guided by cryo-electron microscopy and an in silico model to predict the brain-to-plasma partition coefficient Kp as an important parameter to prioritize compounds for synthesis. The model combined with in vitro and in vivo experiments allowed us to advance compounds with favorable unbound brain-to-plasma ratios (Kp,uu) to cure a CNS disease such as HAT.

Legend

Protein

Chemical

Disease

Primary Citation of related structures